286 results about "Drug formulations" patented technology

Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

Embodiments relate to device, system and methods for personalised drug dosing via a device, the device comprising a first chamber comprising a drug reservoir unit; a second chamber comprising an electronic unit comprising a control component; a third chamber comprising a drug delivery unit and a flow control component controlled via the electronic unit; wherein the device is fully implanted in a subject during its intended operational modes, and wherein the device releases a body temperature stable drug formulation into the subject at a flow rate such that a variation in the flow rate is within ±15% by volume.

Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

The present disclosure relates to pharmaceutical formulations of contrast agents used in magnetic resonance imaging (MRI) and methods of making and purifying the same. More specifically, disclosed are such pharmaceutical formulations of chelate complexes with lanthanide metal ions, such as gadolinium ions, as well as methods for obtaining and purifying the same. In particular, the pharmaceutical formulations are free or substantially free of water molecules coordinated with the lanthanide metal chelate complexes and provide pharmaceutical compositions that are more stable and release less lanthanide ion, specifically gadolinium ion, into the human body when injected as MRI contrast agents as compared to other typically used MRI contrast agents.

The invention relates to the technical field of medicine formulas, in particular to a fluralamide moxidectin composite drop and a preparation process thereof. The invention relates to a fluralan-moxidectin emulsion which is prepared from the following raw materials in percentage by mass: 26 to 30 percent of fluralan, 1.1 to 1.7 percent of moxidectin, 32 to 36 percent of solvent, 0.1 to 0.3 percent of butylated hydroxytoluene, 10 to 16 percent of polymer carrier and the balance of tetrahydrofuran polyethylene glycol ether. The coexisting drug is stabilized through the core-shell structure polymer carrier, phase separation is prevented, a neutral environment is maintained, long-acting stability is ensured, the transdermal absorption rate is optimized, skin irritation is reduced, and the synergistic drug effect is improved. Meanwhile, the slow release period of the medicine is prolonged, the metabolic interference and accumulated toxicity are reduced, and the dissolution efficiency and the skin mildness are both considered.

Disclosed is an acylated insulin, a pharmaceutical formulation thereof, a pharmaceutical composition thereof with a long-acting GLP-1 compound, and a medical use of the acylated insulin, the pharmaceutical formulation and the pharmaceutical composition. Compared with insulin degludec or other insulin derivatives, the acylated insulin has an unexpected, significantly increased drug effect, a longer duration of action, a longer in vivo half-life, an excellent bioavailability, as well as better physical and chemical stabilities.

Provided is a composition comprising aflibercept and a variant thereof, wherein the variant is a truncation variant with a truncated VEGF binding portion of aflibercept, and wherein the content of the truncation variant is less than or equal to about 20% by mass percentage. Also provided is a pharmaceutical formulation comprising the composition. Further, provided are a method for detecting the variant and use of the variant in quality inspection or quality control of an aflibercept-containing product.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The invention discloses a drug formula optimization system based on artificial intelligence, and relates to the technical field of drug formula optimization, and the system comprises a data input module which is used for receiving and processing drug component information from a drug research and development database, clinical test results and laboratory test data, and extracting key features based on the drug component information, the medicine component information comprises biological activity, chemical properties and formula ratio of the compound. The drug formula optimization system based on artificial intelligence integrates data input, intelligent analysis, formula iteration, simulation test and decision optimization, realizes full-process automatic processing of drug formula optimization, reduces manual intervention and tedious experimental processes, shortens the drug research and development period, improves the drug formula efficiency, and reduces the labor intensity of a user. And the drug formula effect can be accurately predicted.

Systems and methods that an individual may use for disposing of unwanted pharmaceutical formulation. More specifically, systems and methods that an individual may use for disposing of unwanted pharmaceutical formulations that include receiving a disposal container including a pharmacological agent activity mitigation component and combining the unwanted pharmaceutical formulation with the pharmacological agent activity mitigation component in the disposal container are provided. The systems and method may further include a direct mail mailer for sending the disposal container and pharmacological agent activity mitigation component to the user.

Disclosed is a novel quercetin-hexahydric alcohol cocrystal. These cocrystals have been developed as innovative pharmaceutical formulations. The present invention encompasses methods for producing these cocrystal materials, as well as their application as bioenhancers for active pharmaceutical ingredients, phytochemicals, vitamins, and minerals. The disclosed process for preparing quercetin-hexahydric alcohol cocrystals involves the formation of the cocrystal through a kinetic-controlled co crystallization process, enhancing the bioavailability and efficacy of bioactive compounds.

The invention relates to a salt form of a pyrrole sulfonamide acid inhibitor as well as a preparation method and application of the salt form. Specifically, the invention discloses a compound shown as a formula (I), n = 0.1-2.0, and HA is an organic acid or an inorganic acid. The compound has the characteristics of convenience in storage, long-term stability of the product and simple preparation method, meets the industrial production requirements, and meets the development requirements of clinical pharmaceutical preparations. The compound disclosed by the invention can be used for preparing a potassium ion competitive acid blocker and preparing a medicine for treating gastric acid related diseases. # imgabs0 #

An embodiment relates to systems and methods to deliver medications precisely within body of a subject as prescribed and tailored to individual needs. The system comprises a miniaturized implantable drug delivery device that dispenses drugs subcutaneously with controlled precision; a stable drug formulation that remains effective at body temperature; a biosensor that continuously monitors at least one of a drug level and health markers; and an analytics platform that analyses data to optimize drug delivery in real-time, ensuring highly personalized and effective patient care.

Provided herein are crystalline solid forms of gusacitinib and Compound (1): (1). The present disclosure also provides pharmaceutical formulations comprising said crystalline solid forms, as well as uses thereof.

Devices, kits, and methods for heating a drug formulation in an injection device are disclosed. An embodiment of the device includes a housing enclosure having a first housing shell and a second housing shell, and a plurality of bladders adjacent to an inner surface of the first housing shell and adjacent to an inner surface of the second housing shell. The housing enclosure is designed to receive the injection device. When an edge of the first housing shell and an edge of the second housing shell couple, the bladders contact a portion of the injection device and heat the drug formulation in the injection device. An embodiment of the kit includes this device and the injection device.

The present invention provides binary or ternary complexes capable of improving the stability of a drug, particularly inhibiting transesterification within a drug molecule. The compound can also improve the pharmacodynamic preparation performance of the medicine and improve the safety and effectiveness of the medicine.

A liquid pharmaceutical formulation, suitable for lyophilization, comprising nerve growth factor (NGF) and at least one pharmaceutically acceptable excipient.

The invention belongs to the technical field of biological medicine, and particularly relates to a CD44 / GSH dual-response eutectic drug delivery system and a preparation method thereof.The CD44 / GSH dual-response eutectic drug delivery system comprises a microneedle array composed of a biodegradable polymer matrix formed by hyaluronic acid (HA) and poly (lactic-co-glycolic acid) (PLGA), and the microneedle array comprises a plurality of microneedles; a microneedle comprising a pharmaceutical formulation of a resveratrol-berberine co-crystal integrated into the polymer matrix; wherein the polymer matrix comprises a disulfide bond that is a glutathione (GSH) responsive switch; wherein the hyaluronic acid is capable of specifically targeting a CD44 receptor; wherein the disulfide bond can be cleaved under the condition that the concentration of glutathione in a target tissue is increased, thereby releasing the resveratrol-berberine eutectic pharmaceutical formulation; and wherein the microneedle array is configured to percutaneously deliver the resveratrol-berberine co-crystal pharmaceutical formulation to the target tissue.

The invention discloses a medicine compatibility effective component analysis method, and relates to the technical field of medicine compatibility, and the method comprises the following steps: carrying out data integration based on pre-obtained patient basic information and traditional Chinese medicine prescription data to generate a comprehensive data set, extracting effective components from a preset unified component database to generate a component list, and storing the component list in a database; analyzing the acting target spots through preset target spot mapping to generate a target spot matrix; dynamically generating pathological weight parameters based on the target matrix and basic disease data of the patient, and predicting a pharmacological effect according to a target overlapping degree to generate an effect prediction result; based on the effect prediction result and the component list, a risk level evaluation coefficient is calculated by applying a risk weight algorithm, and then a risk level is obtained through decision making; based on the risk level, a compatibility effective component analysis report is generated, and the problem of limitation existing in the current medicine compatibility effective component analysis process is solved.

The present invention provides: a stable fibrin clot-soluble protein excellent in production in protein-expressing cells in a serum-free medium and suppressing the production of impurities such as degradation products; a pharmaceutical formulation containing the protein; and a production method for the protein and pharmaceutical formulation.

The present invention relates to a composition comprising 5-methoxy-N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof formulated by using templated carrier particles, as well as to a tablet, in particular a sublingual tablet, comprising the same. The compositions and in particular the tablets of the present invention are particularly useful in the treatment or prevention of psychiatric disorders.

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts, pharmaceutical formulations comprising them as well as their phosphate ester prodrugs, and their uses alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and / or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or the upregulation of the NO pathway is desirable. The compounds are of Formula I

Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

Described herein are systems and methods that combine at least three different detection modalities to characterize the stability of drug formulations, and sample plates for use with the systems and methods. The systems may include a clamp configured to apply a force to the sample plates that trap and pressurize air above an inlet and / or outlet of sample holders included in the sample plates. Measurements of various parameters of the samples may be obtained in tandem or simultaneously with a single instrument, which reduces sample volume requirements.

Cosmetic and pharmaceutical formulations comprising specific amino acid combinations are described herein. Such formulations strengthen and enhance skin epithelial cell barrier function, thereby reducing moisture loss from the skin and restoring skin's structural integrity, epithelial differentiation, intercellular adhesion, and intracellular signaling and / or promoting maintenance of these features. Additional formulations described here comprise a therapeutically effective amount of free amino acids and a therapeutically effective amount of a plant extract for skin barrier repair. Methods for administering these formulations for cosmetic and / or therapeutic purposes and uses thereof for same are also described herein, including the use thereof in the preparation of medicaments.

The disclosure provides for improved pharmaceutical compositions containing an active pharmaceutical ingredient and a non-polymeric lubricant and methods of manufacturing the same. In particular, the compositions are prepared using thermal processing or solvent spraying and provide improved properties as well as more efficient methods of manufacture.